Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis

中止 医学 乙型肝炎表面抗原 HBeAg 内科学 胃肠病学 恩替卡韦 失代偿 肝细胞癌 乙型肝炎 乙型肝炎病毒 拉米夫定 免疫学 病毒
作者
Samuel Hall,Sara Vogrin,Olivia Wawryk,Gareth Burns,Kumar Visvanathan,Vijaya Sundararajan,Alexander Thompson
出处
期刊:Gut [BMJ]
卷期号:: gutjnl-323979 被引量:57
标识
DOI:10.1136/gutjnl-2020-323979
摘要

Background and aims Sustained virological suppression and hepatitis B surface antigen (HBsAg) loss have been described after nucleot(s)ide analogue (NA) discontinuation for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). We performed a meta-analysis of the clinical outcomes after NA discontinuation for HBeAg-negative CHB. Methods Studies involving NA cessation in HBeAg-negative CHB individuals with a median follow-up of ≥12 months were included. Participants were HBeAg-negative at the time of NA initiation. Random effects meta-analyses were performed for the following clinical outcomes: (1) virological relapse (VR) at 6 and 12 months; (2) clinical relapse (CR) at 6 and 12 months and (3) HBsAg loss. Effect of other variables was estimated using subgroup analysis and meta-regression. Studies including patients stopping entecavir (ETV) and/or tenofovir disoproxil fumarate (TDF) were considered separately to studies including patients stopping older generation NA. Results N=37 studies met inclusion criteria. Cumulative incidence of VR and CR after stopping ETV/TDF was 44% and 17% at 6 months and 63% and 35% at 12 months. Similar relapse rates were observed after stopping older NAs. Among patients stopping ETV/TDF, TDF cessation was associated with increased CR rates at 6 months versus ETV. There was an association between follow-up ≥4 years and HBsAg loss rates when stopping older NAs. Hepatic decompensation and hepatocellular carcinoma were rare but occurred more frequently in studies including cirrhotic individuals. Conclusion VR is common after NA discontinuation, however, CR was only seen in one-third of patients at 12 months. Stopping NA therapy can be followed by HBsAg clearance, and rates are higher with longer follow-up.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Philadelphus发布了新的文献求助10
1秒前
einuo完成签到,获得积分10
1秒前
AKYDXS完成签到,获得积分10
4秒前
昏睡的蟠桃应助Llllll采纳,获得200
4秒前
科研通AI2S应助hao采纳,获得10
4秒前
5秒前
5秒前
香蕉觅云应助阿湫采纳,获得10
6秒前
星辰大海应助星辰采纳,获得10
6秒前
阿卡宁完成签到,获得积分10
6秒前
lzw完成签到 ,获得积分10
6秒前
沉静烧仙草完成签到,获得积分20
7秒前
烟花应助嘉嘉琦采纳,获得10
7秒前
隐形曼青应助科研通管家采纳,获得10
7秒前
Hello应助科研通管家采纳,获得10
8秒前
Ava应助科研通管家采纳,获得10
8秒前
上官若男应助科研通管家采纳,获得10
8秒前
8秒前
赘婿应助科研通管家采纳,获得10
8秒前
烟花应助科研通管家采纳,获得10
8秒前
FashionBoy应助科研通管家采纳,获得10
8秒前
英俊的铭应助科研通管家采纳,获得10
8秒前
在水一方应助科研通管家采纳,获得10
8秒前
accepted应助科研通管家采纳,获得10
8秒前
脑洞疼应助科研通管家采纳,获得10
8秒前
8秒前
cdh1994应助kcmat采纳,获得10
8秒前
我是老大应助科研通管家采纳,获得10
8秒前
乐乐应助科研通管家采纳,获得10
8秒前
FashionBoy应助科研通管家采纳,获得10
8秒前
8秒前
上官若男应助科研通管家采纳,获得10
8秒前
8秒前
8秒前
8秒前
我是老大应助科研通管家采纳,获得30
8秒前
脑洞疼应助科研通管家采纳,获得20
9秒前
科目三应助科研通管家采纳,获得30
9秒前
9秒前
完美世界应助科研通管家采纳,获得10
9秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048